Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody maintains its neutralizing activity against a mutation in the receptor-binding domain (RBD) of SARS-CoV-2, called L452R, found in the California variant (B.1.427/B.1.429).

Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection

– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –

Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant

Eli Lilly

Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-administered with VIR-7831 in low-risk adult patients with mild to moderate COVID-19. Results showed that bamlanivimab 700 mg co-administered with VIR-7831 500 mg demonstrated a 70% relative reduction in persistently high viral load at day seven compared to placebo, meeting the primary endpoint.

Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients

GlaxoSmithKline

Eli Lilly & Co. , Vir Biotechnology Inc. and GlaxoSmithKline PLC on Monday reported positive data from a Phase 2 trial evaluating the combination of two monoclonal antibodies in treating low-risk adult COVID-19 patients. The trial found combining Lilly's bamlanivimab with Vir's VIR-7831 showed a 70% reduction in persistently high viral load at day 7 compared to placebo.

Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7

INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p 5.27; cycle threshold value < 27.5) at day 7 compared to placebo, meeting the primary endpoint.

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition. What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses.

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

GlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for mild-to-moderate COVID-19 in adults and adolescents aged 12 and older who are at risk of hospitalization or death. The companies said early data from a Phase 3 trial found the treatment showed an 85% reduction in hospitalization or death compared to placebo.

GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatment

GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with mild-to-moderate COVID-19 who are at risk for progression to hospitalization or death.

GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19

iShares Nasdaq Biotechnology ETF

Novavax

Ocugen, Inc.

SPDR S&P Biotech ETF

Short-term investors may not see the long-term potential.

Here's Why Clinical-Stage Biotechs Get Hit Harder During a Market Decline

Alnylam Pharmaceuticals

Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136). The therapy demonstrated an 85% reduction in hospitalization or death in the VIR-7831 arm than the placebo.

Alnylam, Vir Biotech Deprioritize COVID-19 Drug Development In Hushed Manner

Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?

Investors are excited about the potential of the company's investigational coronavirus therapy.

Why Vir Biotechnology Stock Soared Today

Shares of Vir Biotechnology spiked 36% on Thursday after the company announced that its COVID-19 antibody treatment significantly reduced hospitalizations and deaths for high-risk patients during a clinical trial. The San Francisco-based drugmaker said it will seek emergency use authorization for the drug in the US and in other countries after the ongoing trial is completed upon the recommendation of an Independent Data Monitoring Committee.

Vir Biotechnology spikes 36% after it says its COVID-19 treatment reduced hospitalizations and deaths in high-risk patients

GlaxoSmithKline and Vir Biotechnology said Wednesday their antibody drug reduced the risk of hospitalization and death in high-risk Covid-19 patients — and Vir stock catapulted Thursday. The post Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New Test appeared first on Investor's Business Daily.

Vir Stock Catapults After Its GSK-Partnered Covid Drug Succeeds In New Test

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) has increased by over 50% pre-market. This is why it happened.

VIR Stock Price Increases Over 50% Pre-Market: Why It Happened

An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profound efficacy. The antibody treatment is being developed under a collaboration between Vir Biotechnology Inc's (NASDAQ: VIR) and GlaxoSmithKline Plc' (NYSE: GSK).

Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod

– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death –

Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19

The relationship could result in a marriage down the line.

After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir?

The biotech's pipeline gets a seal of approval.

Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

Bearish commentary from an analyst may be to blame.

Why Vir Biotechnology Stock Is Falling Today

Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?

VIR stock is plunging on some pretty unfavorable news about a trial being suspended for the company's prospective Covid-19 vaccine. The post VIR Stock: Why Vir Biotechnology Is Plunging Today appeared first on InvestorPlace.

VIR Stock: Why Vir Biotechnology Is Plunging Today

The company announced that a data and safety monitoring board had recommended ending a trial of its experimental antibody therapy in hospitalized Covid-19 patients.

Vir Shares Plummeted Today. What to Know.

The company provided a discouraging regulatory update.

News for Vir Biotechnology Stock (VIR)